WFG Advisors LP increased its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 2,650.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 29,784 shares of the company’s stock after acquiring an additional 28,701 shares during the period. WFG Advisors LP’s holdings in Teva Pharmaceutical Industries Limited were worth $989,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. San Francisco Sentry Investment Group CA acquired a new stake in shares of Teva Pharmaceutical Industries Limited during the second quarter worth $106,000. Kistler Tiffany Companies LLC increased its stake in Teva Pharmaceutical Industries Limited by 74.7% in the 2nd quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock valued at $122,000 after buying an additional 1,571 shares during the last quarter. FNY Managed Accounts LLC acquired a new stake in Teva Pharmaceutical Industries Limited in the 1st quarter valued at $123,000. Bronfman E.L. Rothschild L.P. increased its stake in Teva Pharmaceutical Industries Limited by 2.6% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock valued at $123,000 after buying an additional 94 shares during the last quarter. Finally, Sterling Investment Advisors Ltd. increased its stake in Teva Pharmaceutical Industries Limited by 2.6% in the 1st quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock valued at $125,000 after buying an additional 100 shares during the last quarter. Institutional investors and hedge funds own 56.76% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Teva Pharmaceutical Industries Limited (TEVA) Shares Bought by WFG Advisors LP” was reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/10/16/teva-pharmaceutical-industries-limited-teva-shares-bought-by-wfg-advisors-lp.html.

Several brokerages have issued reports on TEVA. BidaskClub lowered shares of Teva Pharmaceutical Industries Limited from a “sell” rating to a “strong sell” rating in a research note on Friday. Piper Jaffray Companies set a $23.00 price target on shares of Teva Pharmaceutical Industries Limited and gave the company a “hold” rating in a research note on Friday, October 6th. Wells Fargo & Company set a $20.00 price target on shares of Teva Pharmaceutical Industries Limited and gave the company a “hold” rating in a research note on Wednesday, October 4th. Morgan Stanley set a $15.00 price target on shares of Teva Pharmaceutical Industries Limited and gave the company an “underweight” rating in a research note on Thursday, October 5th. Finally, Cowen and Company reiterated a “market perform” rating and issued a $18.00 price target (down from $30.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, October 4th. Five analysts have rated the stock with a sell rating, eighteen have given a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $27.63.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded down 1.035% during mid-day trading on Monday, reaching $14.825. 9,359,782 shares of the company’s stock were exchanged. The stock’s market cap is $15.06 billion. Teva Pharmaceutical Industries Limited has a 52-week low of $14.30 and a 52-week high of $44.42. The company has a 50-day moving average of $16.73 and a 200-day moving average of $26.05.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.07). The business had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. Teva Pharmaceutical Industries Limited’s revenue for the quarter was up 12.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.25 EPS. Equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.24 earnings per share for the current year.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.